The impact of diabetes mellitus on treatment and outcomes of rheumatoid arthritis at 5-year follow-up: results from a multi-ethnic Asian cohort

Chuanhui Xu 1, Mei Yun Yong 1, Ee Tzun Koh 1, Rinkoo Dalan 2 and Khai Pang Leong 1; and the TTSH Rheumatoid Arthritis Study Group

Abstract

Objectives We evaluated the impact of type 2 diabetes mellitus (T2DM) on RA treatment and outcomes in a longitudinal RA cohort.

Methods We analysed data collected in the period 2001–2013 involving 583 RA patients, including demographics, diabetes diagnosis, clinical features, treatment, ACR functional class, HAQ, and quality-of-life measurement using the Short-Form 36.

Results Seventy-seven (13.2%) of the RA patients had T2DM. DAS28 was not different in patients with T2DM at 5 years post-RA diagnosis. Fewer T2DM patients received MTX than those without T2DM (51% vs 80%, P < 0.001). Using univariate analysis, T2DM patients were more likely to experience poorer outcomes in terms of ACR functional status (P = 0.009), joint surgery (P = 0.007), knee arthroplasty (P < 0.001) and hospital admissions (P = 0.006). Multivariate regression analyses showed more knee arthroplasty (P = 0.047) in patients with T2DM.

Conclusion Fewer patients with T2DM received MTX compared with those without T2DM. Patients with RA and T2DM were at higher risk of knee arthroplasty than RA patients without T2DM.

Key words: rheumatoid arthritis, diabetes mellitus, outcomes, treatment

Introduction

RA is a chronic systemic inflammatory disorder affecting ~1–1.5% of the population worldwide [1–3]. The concept of treating to target in RA [4] and the availability of efficacious agents [5] have improved the control of disease in the past three decades. However, metabolic co-morbidities complicating RA treatment are increasingly being encountered. The EULAR proposed specific recommendations for the detection and management of specific co-morbidities for patients with RA and other forms of inflammatory arthritis [6, 7]. The impacts of diabetes mellitus on treatment and outcomes have not been well investigated, although there are some studies based on questionnaire survey and electronic health record-based registry [8, 9].

Type 2 diabetes mellitus (T2DM) is a substantial global burden. Systemic chronic inflammation is recognized as the underlying aetiology of a variety of diseases, such
as diabetes mellitus, autoimmune diseases and neuro-degenerative diseases [10]. The central role of metabolism in the modulation of immune responses is increasing being recognized in autoimmune disease [11]. The hyperglycaemic status can influence both innate and adaptive immune responses [12]. The concomitant systemic chronic inflammation and altered immune response in diabetes mellitus might alter the disease characteristics of RA. Moreover, the microvascular and macrovascular complications from diabetes mellitus might influence patients’ functional status and choices of treatment. Besides cardiovascular complications, diabetes mellitus also causes a variety of musculoskeletal complications [13].

It is important to address the impact of T2DM on RA, given their shared underlying systemic chronic inflammation and overlapping propensity to cause cardiovascular and musculoskeletal complications. Our previous studies demonstrated that RA is an important cause of quality-of-life impairment, disability and premature death in Singapore, a multi-ethnic Asian society [14–16]. The aim of this study was to investigate whether the presence of T2DM among patients with RA leads to differences of clinical features and outcomes in a multi-ethnic Asian cohort.

Methods

Study population

The Tan Tock Seng Hospital (TTSH) RA Registry has been following patients longitudinally since 2001. All the patients are managed by doctors in the Department of Rheumatology, Allergy and Immunology at TTSH, Singapore, a public hospital that is a tertiary rheumatology referral centre. The data in this study were extracted from the TTSH RA registry. All patients fulfil the 1987 ACR revised criteria for RA or the 2010 ACR/EULAR criteria [17, 18]. The diagnosis of T2DM is physician reported, based on Singapore clinical practice guidelines of diabetes mellitus [19]. Patients who entered the study provided written informed consent according to the Declaration of Helsinki. The Registry is approved by the institutional review board (National Healthcare Group’s Domain Specific Review Board Reference Number: 2014/01141).

Data collection

The disease registry collected the following at baseline and thereafter 6-monthly: socio-demographic data, clinical data including the presence of co-morbidities, extra-articular features, physician’s global assessment of RA activity, damaged joint counts, Disease Activity Score of 28 joints (DAS28), visual analog scale score for patient-reported general health, drug treatment, ACR functional class, HAQ, quality-of-life measurement using the Short-Form 36 (SF-36), and selected laboratory tests. Details of the Registry have been published [15]. To investigate the long-term impact of T2DM on patients with RA, 583 patients with outcomes at 5 years after diagnosis were selected for analysis.

Statistical method

We displayed descriptive data of demographic characteristics, clinical features and outcomes of RA, categorical variables by frequency and percentage, and continuous variables by median and interquartile. We compared differences in demographics, serology, clinical features, co-morbidities and outcomes between T2DM and non-T2DM RA patients using Pearson’s $\chi^2$ or Fisher’s exact test for categorical variables and the Mann–Whitney U-test for non-parametric continuous variables. After adjustment of patient’s background variables (i.e., age, gender (male vs. female), ethnicity, smoking, hypertension, hyperlipidaemia and use of medications), we performed logistic multivariate regression analyses for categorical outcomes and linear multivariate regression for continuous outcomes. We used STATA software v.15 (Stata Corp., College Station, TX, USA). Complete case analysis was used for missing data. All tests were conducted at the 5% level of significance, reporting the odds ratio (OR), $\beta$ coefficient value, $P$-value and corresponding 95% CI reported where applicable.

Results

Baseline demographic characteristics

Data were collected from 583 RA patients with outcome metrics documented 5 years after diagnosis, among whom 77 (13.2%) had T2DM. Of these 77 patients, 26 were diagnosed to have T2DM after the onset of RA. The median duration of T2DM was 6 years. There were 11 patients on insulin and 52 patients on oral hypoglycaemic agents. The T2DM patients were older (69 vs 55 years, $P < 0.001$), and the prevalence was higher in Malays (26%) and Indians (24%) when compared with Chinese (11%; $P = 0.005$). There was no difference in gender or smoking history (Table 1).

Differences of clinical features, co-morbidities and outcomes between diabetic and non-diabetic RA patients

A lower proportion of patients with T2DM received MTX (39 of 77, 51%) compared with those without T2DM (406 of 506, 80%; $P < 0.001$), although there was no difference with regard to cumulative doses of MTX (1447 mg vs 1809 mg, $P = 0.052$; Table 2). There was numerically less use of LEF (5% vs 13%, $P = 0.058$; Table 2). Hypertension, hyperlipidaemia, cardiovascular events and renal disease occurred more commonly in T2DM patients (Table 2). The T2DM patients were more likely to experience poor ACR functional status ($P = 0.009$), joint surgery (10% vs 4%, $P = 0.007$), knee arthroplasty (9% vs 2%, $P < 0.001$) and hospital admission (44% vs 29%, $P = 0.006$; Table 3). There was no statistical difference in serological results or disease activity. The use of prednisolone,
### Table 1: Demographic characteristics of diabetic and non-diabetic RA patients

| Characteristic               | T2DM (n = 77) | Non-T2DM (n = 506) | P-value |
|-----------------------------|---------------|--------------------|---------|
| Age, median (IQR), years   | 60 (54–68)    | 55 (48–64)         | <0.001  |
| Female, n (%)               | 64 (83)       | 426 (84)           | 0.811   |
| Ethnicity                   |               |                    | 0.006   |
| Chinese, n (%)              | 52 (68)       | 422 (83)           |         |
| Malay, n (%)                | 12 (16)       | 35 (7)             |         |
| Indian, n (%)               | 12 (16)       | 38 (8)             |         |
| Others, n (%)               | 1 (1)         | 11 (2)             |         |
| Smoking                     |               |                    | 0.895   |
| Ever, n (%)                 | 10 (1)        | 63 (1)             |         |
| RF positive<sup>a</sup>     | 60 (78)       | 406 (80)           | 0.742   |
| Anti-CCP positive<sup>b</sup> | 49 (64)     | 357 (71)           | 0.688   |
| Disease duration, median (IQR), years | 5.6 (5.3–7.0) | 5.5 (5.3–7.1) | 0.537   |
| Duration of T2DM, median (IQR), years | 6 (4–10)     | –                  |         |

Values are given as the median (IQR) for non-parametric continuous variables and n (%) for categorical variables. The $\chi^2$ test for categorical variables and Mann–Whitney U-test for non-parametric continuous variables were performed for statistical analyses. <sup>a</sup>Three cases with unknown status. <sup>b</sup>Fifty-eight cases with unknown status. IQR: interquartile range; T2DM: type 2 diabetes mellitus.

### Table 2: Clinical features and co-morbidities of diabetic and non-diabetic RA patients at 5 years after diagnosis

| Characteristic               | T2DM (n = 77) | Non-T2DM (n = 506) | P-value |
|-----------------------------|---------------|--------------------|---------|
| Deformity of joints, median (IQR) | 0 (0–2)   | 0 (0–2)            | 0.697   |
| DAS28, n (%)                 | 39 (51)       | 406 (80)           | 0.771   |
| DAS28 ≤ 2.6                  | 35 (45)       | 251 (50)           |         |
| 2.6 < DAS28 ≤ 3.2            | 17 (22)       | 95 (19)            |         |
| 3.2 < DAS28 ≤ 5.1            | 22 (29)       | 145 (29)           |         |
| 5.1 < DAS28                  | 3 (4)         | 15 (3)             |         |
| Medication use, n (%)        |               |                    |         |
| Prednisolone                 | 72 (94)       | 478 (94)           | 0.734   |
| Cumulative prednisolone per patient, median (IQR), mg | 3661 (2037–7221) | 3611 (1652–6013) | 0.227   |
| MTX                         | 33 (43)       | 241 (48)           | 0.434   |
| Cumulative MTX per patient, median (IQR), mg | 1447 (0–2572) | 1809 (382–3115) | 0.052   |
| SSZ                         | 56 (73)       | 330 (65)           | 0.194   |
| LEF                         | 4 (5)         | 65 (13)            | 0.058   |
| Gold                        | 2 (3)         | 17 (3)             | >0.999  |
| Penicillamine                | 2 (3)         | 15 (3)             | >0.999  |
| AZA                         | 3 (4)         | 14 (3)             | 0.481   |
| CSA                         | 2 (3)         | 3 (1)              | 0.132   |
| Biologics                    | 1 (1)         | 5 (1)              | 0.574   |
| Drug adherence, n (%)        | 66 (86)       | 419 (83)           | 0.525   |
| Subcutaneous nodules, n (%)  | 3 (4)         | 24 (5)             | >0.999  |
| Interstitial lung disease, n (%) | 0 (0)     | 14 (3)             | 0.234   |
| Hypertension, n (%)          | 54 (74)       | 157 (31)           | >0.999  |
| Hyperlipidaemia, n (%)       | 38 (49)       | 132 (26)           | >0.999  |
| Cardiovascular event, n (%)  | 10 (13)       | 32 (6)             | 0.035   |
| Cancer, n (%)                | 1 (1)         | 13 (3)             | >0.999  |
| Liver disease, n (%)         | 9 (12)        | 37 (7)             | 0.185   |
| Renal disease, n (%)         | 11 (14)       | 16 (3)             | >0.999  |
| Osteoporosis/fracture, n (%) | 20 (26)       | 97 (19)            | 0.171   |

Values are given as the median (IQR) for non-parametric continuous variables and n (%) for categorical variables. The $\chi^2$ test for categorical variables and Mann–Whitney U-test for non-parametric continuous variables were performed for statistical analyses. IQR: interquartile range; T2DM: type 2 diabetes mellitus.
other DMARDs, including HCQ, SSZ, gold, penicillamine, AZA and CSA, and biologics, was similar in both groups (Table 2). There was also no difference in the frequency of other co-morbid conditions (osteoporosis, fracture and infections) and drug adherence (Table 2).

Multivariate analyses of the impact of T2DM on outcomes of patients with RA

We performed multivariate regression analyses, adjusting for age, gender, ethnicity, smoking status, hypertension, hyperlipidaemia and use of medications. The results showed a higher risk for knee arthroplasty (adjusted OR: 3.480, 95% CI: 1.016, 11.920, \( P = 0.047 \); Table 4). There was no statistically significant difference in disease activity, ACR functional status, HAQ score, infection rate and admissions (Table 4). The outcomes, including ACR functional status, HAQ and joint surgery, were independent of the duration of T2DM upon further analyses by regression test (data not shown).

Discussion

We found that T2DM is more prevalent in Malays and Indians than Chinese patients. Fewer T2DM patients received MTX. They might have a higher risk of knee surgery.

The overall prevalence of T2DM was 13.2% in patients with RA in our cohort. The prevalence of T2DM in the general population (age range: 18–69 years old) in Singapore is 11.3% [20], with differences in age and gender compared with patients in our cohort. An Italian cross-sectional study showed that the prevalence of diabetes mellitus in patients with RA is 13.6%, which is higher than the age- and gender-matched population, which is 8.4% [21]. A meta-analysis including a total of 11 case–control studies and 8 cohort studies also confirmed that RA is associated with increased risk of diabetes mellitus [22]. It has been established that underlying inflammation, characterized by elevated CRP and IL-6, plays a role in development of T2DM [23]. In addition, the use of corticosteroids might predispose the development of T2DM.

MTX remains the anchor drug in RA therapy [5]. The benefits of MTX are not limited only to the control of RA, but include the reduction of cardiovascular events [24, 25]. The combination of MTX and biologic therapy is associated with a lower rate of large joint replacement than with biologic agents alone, supporting the hypothesis that low-dose MTX is chondroprotective [26, 27].
spite of achieving disease remission [30]. Previous studies showed poor functional status in RA patients with T2DM [9]. Indeed, the finding that co-morbidities contribute to disability in spite of quiescent RA highlights the importance of managing such conditions, especially T2DM [30–33].

The strength of our study is the large number of patients with long-term follow-up in an Asian context. One limitation of our study is its observational nature; hence, we cannot evaluate the direct impact of T2DM on outcomes of RA patients. A second limitation is that obesity or BMI might be an important potential confounder, but these data are available for only 313 of 582 patients. Third, the diagnosis of T2DM was physician reported, and an oral glucose tolerance test was not performed on every patient. Fourth, although it is independent of the duration of T2DM, we are not certain whether the poorer outcomes in patients with T2DM are dependent on the glycosylated haemoglobin A1c level, which, unfortunately, is largely unavailable.

In summary, the prevalence of T2DM in RA patients is higher than that in the general population, with an inter-ethnicity difference. MTX was used less in patients with T2DM. T2DM might be an independent risk factor for a higher risk of knee arthroplasty. More studies are warranted to investigate whether good control of T2DM improves outcomes in patients with RA.

### Acknowledgements

We thank Ms Amelia Lim Qiu Ru, Mr Chua Kia Wei and Ms Choong Ying Qi for the assistance with data collection.

#### Table 4

Multivariate regression analysis of the impact of T2DM on RA outcomes

| Outcome                          | Non-T2DM          | T2DM              | P-value |
|---------------------------------|-------------------|-------------------|---------|
| DAS28                           | Reference         | 0.923 (0.566–1.503) | 0.744    |
| ACR status                      | Reference         | 1.802 (0.968–3.353) | 0.063    |
| PGA                             | Reference         | –1.497 (–7.467 to 4.472) | 0.622   |
| DGA                             | Reference         | –1.998 (–6.310 to 2.314) | 0.363   |
| VAS                             | Reference         | 2.446 (–3.962 to 8.855) | 0.454    |
| HAQ, median                     | Reference         | 0.129 (–0.010 to 0.267) | 0.068    |
| PF score, median                | Reference         | –1.661 (–8.323 to 5.001) | 0.624    |
| RP score, median                | Reference         | –1.886 (–13.129 to 9.358) | 0.742    |
| BP score, median                | Reference         | –0.492 (–6.978 to 5.994) | 0.882    |
| GH score, median                | Reference         | –1.977 (–7.595 to 3.642) | 0.490    |
| VT score, median                | Reference         | 1.625 (–3.867 to 7.116) | 0.561    |
| SF score, median                | Reference         | –1.338 (–7.975 to 5.299) | 0.692    |
| RE score, median                | Reference         | –1.328 (–11.909 to 9.254) | 0.805    |
| MH score, median                | Reference         | –1.158 (–5.988 to 3.672) | 0.638    |
| RAI, median                     | Reference         | 0.582 (–1.387 to 2.550) | 0.562    |
| Arthroplasty (knee)             | Reference         | 3.480 (1.016–11.920) | 0.047    |
| Infection                       | Reference         | 0.994 (0.305–3.240) | 0.993    |
| Admission                       | Reference         | 1.332 (0.771–2.302) | 0.304    |

Logistic multivariate regression for categorical variables and linear multivariate regression for continuous variables, respectively. T2DM as a risk factor was adjusted to the patient’s background variables (i.e. age, gender, ethnicity, smoking, hypertension, hyperlipidaemia and medications). The β-coefficient is shown for continuous variables and odds ratio for categorical variables. BP: bodily pain; DGA: doctor global assessment; GH: general health; MH: mental health; PF: physical functioning; PGA: patient global assessment; RAI: rheumatology attitude index; RE: role emotional; RP: role physical; SF: social functioning; T2DM: type 2 diabetes mellitus; VAS: visual analog scale; VT: vitality.
The TTSH Rheumatoid Arthritis Study Group consists of Andrea Ang, Angela Li-Huan Chan, Grace Yin Lai Chan, Madelynn Tsu-Li Chan, Faith Li-Ann Chia, Hick Hee Chng, Choong Guan Chua, Hwee Siew Howe, Ee Tzun Koh, Li Wean Koh, Kok Ooi Kong, Weng Giap Law, Samuel Lee Shang Ming, Khai Pang Leong, Tsui Yee Lian, Xin Rong Lim, Jess Mung Ee Loh, Mona Manghani, Justina Wei Lynn Tan, Sze-Chin Tan, Teck Choon Tan, Claire Teo Min-Li, Bernard Yu-Hor Thong and Paula Permatasari Tjokrosaputro.

Funding: This work was supported by the research grants from the Singapore National Medical Research Council (MOH-CSSFD19OCT-0005, NMRC/CG/017/2013 and CGAug16M012).

Disclosure statement: The authors have declared no conflicts of interest.

Data availability statement
The datasets generated for this study are available from the corresponding author upon request.

References
1 Kwon JM, Rhee J, Ku H, Lee EK. Socioeconomic and employment status of patients with rheumatoid arthritis in Korea. Epidemiol Health 2012;34:e2012003.
2 Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735–9.
3 Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22:1–12.
4 Smolen JS, Breedveld FC, Burmester GR et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3–15.
5 Smolen JS, Landewé RBM, Bijlsma JWJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99.
6 Agca R, Heslinga SC, Rollefstad S et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17–28.
7 Bailleul A, Gossec L, Carmona L et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis 2016;75:965–73.
8 Albrecht K, Luque Ramos A, Hoffmann F, Redeker I, Zink A. High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data. Rheumatology (Oxford) 2018;57:329–36.
9 Yun H, Xie F, Chen L et al. Evaluation of the effect of diabetes on rheumatoid arthritis-related outcomes in an electronic health record-based Rheumatology Registry. J Rheumatol 2021;48:992–1001.
10 Furman D, Campisi J, Verdin E et al. Chronic inflammation in the etiology of disease across the life span. Nat Med 2019;25:1822–32.
11 Huang N, Perl A. Metabolism as a target for modulation of rheumatoid arthritis. Rheumatology (Oxford) 2006;45:1023–8.
12 Gupta S, Koirala J, Khardori R, Khardori N. Infections in diabetes mellitus and hyperglycemia. Infect Dis Clin North Am 2007;21:617–38.vii.
13 Merashli M, Chowdhury TA, Jawad AS. Musculoskeletal manifestations of diabetes mellitus. QJM 2015;108:853–7.
14 Koh ET, Leong KP, Tsou IY et al.; Tan Tock Seng Hospital Rheumatoid Arthritis (TTSH RA) Study Group. The reliability, validity and sensitivity to change of the Chinese version of SF-36 in oriental patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:1023–8.
15 Koh ET, Tan JW, Thong BY et al.; TTSH RA Study Group. Major trends in the manifestations and treatment of rheumatoid arthritis in a multiethnic cohort in Singapore. Rheumatol Int 2013;33:1693–703.
16 Lim XR, Xiang W, Tan JWL et al.; TTSH Rheumatoid Arthritis Study Group. Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis patients. Int J Rheum Dis 2019;22:1679–85.
17 Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
18 Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
19 Singapore Ministry of Health, Clinical Practice Guideline of Diabetes Mellitus. https://www.moh.gov.sg/docs/librariesprovider4/guidelines/cpg_diabetes-mellitus-booklet-jul-2014.pdf (24th March 2021, date last accessed).
20 Ministry of Health Survey, National Health Survey 2010, Singapore. Singapore: Epidemiology and Disease Control Division, Ministry of Health, 2011.
21 Ruscitti P, Ursini F, Cipriani P et al. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: results from a cross-sectional study. Medicine (Baltimore) 2017;96:e7896.
22 Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol 2015;33:115–21.
23 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327–34.
24 Westlake SL, Colebatch AN, Baird J et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010;49:295–307.
25 Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173–7.

26 Asai S, Kojima T, Oguchi T et al. Effects of concomitant methotrexate on large joint replacement in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a multicenter retrospective cohort study in Japan. Arthritis Care Res (Hoboken) 2015;67:1363–70.

27 Asai S, Takahashi N, Funahashi K et al. Concomitant methotrexate protects against total knee arthroplasty in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. J Rheumatol 2015;42:2255–60.

28 Mori S, Arima N, Ito M et al. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One 2018;13: e0203084.

29 Montaudié H, Sbidian E, Paul C et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):12–8.

30 Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784–92.

31 van den Hoek J, Roorda LD, Boshuizen HC et al. Long-term physical functioning and its association with somatic comorbidity and comorbid depression in patients with established rheumatoid arthritis: a longitudinal study. Arthritis Care Res (Hoboken) 2013;65:1157–65.

32 Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011;50:381–8.

33 Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:536–41.